Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer

Table 4

Univariate and multivariate analyses for CSS in fifty patients with stage I CRC.

Parameter	Univariate analyses		Multivariate analyses
	HR (95% CI)		HR (95% CI)
Age
≤68 years	1
>68 years	1.2 (0.5–2.6)	0.642
Gender
Male	1
Female	1.2 (0.5–2.8)	0.537
Size
≤3 cms	1
>3 cms	0.8 (0.4–1.9)	0.783
Site
Right colon	1
Left colon	0.8 (0.2–2.9)
Rectum	1.9 (0.6–5.5)	0.241
pT
T1	1
T2	0.4 (0.07–2.3)	0.139
Nodal micrometastases
Absent	1
Present	10.4 (3.6–29.8)	<0.0001
Tumor border configuration
Expansive	1
Infiltrative	2.6 (1.1–6.1)	0.0542
WHO grade
G1	1
G2	0.5 (0.1–1.6)
G3	0.4 (0.08–2.1)	0.322
PDC grade
G1	1
G2	2.6 (1–7.2)
G3	3.6 (1.1–10.9)	0.0112
Tumor budding
Absent	1
Present	2.3 (1–5.2)	0.0334
LVI
Absent	1		1
Present	5.9 (2.6–13.2)	<0.0001	6.2 (2.3–16.6)	0.0003
KRAS mutations
Absent	1
Present	2.4 (1.1–5.4)	0.0228
PIK3CA mutations
Absent	1
Present	3.2 (0.5–17.7)	0.0214
Number of mutations/case
0	1
1	2.7 (1.1–6.2)
2/3	5.6 (1.1–27)	0.039

LVI: lymphovascular invasion.